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Abstract
Background: Video clinics, where patients can have a hospital appointment with their clinician from home, are
emerging in practice, but their effectiveness is unclear. This study will evaluate whether a video clinic implemented
at the University Hospitals Birmingham (UHB) NHS Foundation Trust improves patient satisfaction compared to
standard face-to-face appointments for liver transplant patients.
Methods: This will be a parallel, two-arm, statistician-blinded, randomised evaluation. Clinically stable liver patients
at 1 to 5 years post-transplant (n = 180) will be randomised in equal numbers to video clinic appointments (intervention)
or standard face-to-face appointments (control). The intervention group will have outpatient appointments from home
via a secure video link accessed through the UHB patient portal. All patients will complete baseline questionnaires before
randomisation and electronic follow-up questionnaires after each follow-up appointment during the subsequent
12 months. The primary outcome is the difference in scores between groups for three domains of patient
satisfaction, namely ‘convenience of location’, ‘getting through to the office by phone’ and ‘length of time
waiting’ (modified Visit-Specific Satisfaction Instrument). Secondary outcomes include quality of life (EQ-5D-5 L),
costs, clinical contacts and user experience. Statistical analysis will be descriptive and performed on an intention-to-treat
basis. The primary outcome will be analysed using baseline and 3-, 6-, 9- and 12-month questionnaires (according to
patient follow-up appointment frequency) and comparisons made between study arms. A within-trial cost consequences
analysis will be undertaken on the economic data. Patients (n = 8), carers/family members (n = 6) and health
professionals (n = 14) will be interviewed about the experience of video clinics and the interviews will be analysed
using thematic analysis.
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Discussion: This study will allow an in depth understanding of whether video clinics can improve patient satisfaction
with their care. In addition, the intervention could save patients time and costs, removing the need to travel long
distances for outpatient appointments. Video clinics may be applicable to a wide range of other clinical settings and
health conditions. The study has been approved by the NHS Health Research Authority and a National Research Ethics
Committee (Ref: 17/WM/0338) and research governance approval has been obtained from UHB (Ref: RRK6080).
Trial registration: ISRCTN: 14093266 (25/03/2018; retrospectively registered).
Keywords: Video clinic, Liver transplant, Patient satisfaction, Randomised evaluation, Economic analysis
Background
Increasing the use of technological interventions to im-
prove patient care is becoming more prominent in na-
tional policy, especially for people with chronic conditions
[1–4], with the UK Government having set a target to
offer digital services, including electronic consultations, to
95% of general practice patients by 2020 [2]. Emerging in-
terventions have included online patient access to health
records, computerised therapy, video conferencing and
home sensors [5–8]. The 2016 Wachter Review on Health
Information Technology to Improve Care in England con-
cluded that the English secondary care sector is ready for
a national digital strategy to help create a user-centred in-
frastructure that is high quality and manageable [4].
Video clinics (also known as tele-consultations, virtual
clinics, virtual consultations, e-consultations, remote video
visits, skype consultations or videoconferencing) have
started to emerge in the evidence base for different patient
groups, including patients in primary care [5, 9, 10], sec-
ondary care [5, 10, 11] and integrated/joint care [10, 12,
13]. In secondary care, some studies have used videocon-
ference technology for remote consultation [5, 11, 14, 15].
However, video clinic studies in secondary care have typic-
ally had small sample sizes and differ in their findings. For
example, one study of video clinics in orthopaedics found
higher rates of patient satisfaction in the intervention
group [14], whilst another found similar levels of patient
satisfaction in both intervention and control groups [15].
The evidence is also unclear about the cost-effectiveness
of telehealth services [16]. For example, studies focusing
on teledermatology have found that remote consultation
costs were less than those of conventional medicine when
large geographical distances exist between specialist care
providers and patients [17], and that teledermatology is
not cost-effective for patients travelling smaller distances
[18]. In contrast, a large, well-designed UK study focusing
specifically on the effectiveness of joint consultation be-
tween patients, General Practitioners (GPs) and hospital
specialists found that joint consultations can significantly
increase patient satisfaction with treatment, but were as-
sociated with higher costs over 6 months [13, 19].
Numerous examples of video clinic interventions have
emerged in clinical practice in recent years in the UK [20,
21] and America [22]. However, current evidence does not
clearly show the benefits of video clinics in secondary care
and there is a lack of large well-designed studies assessing
the effectiveness of video clinics to facilitate outpatient
appointments in patients’ homes. There is an ongoing
need for randomised controlled e-health studies and
high-quality evaluations that include research on patient
perspectives, satisfaction and costs [11, 23–25].
Video clinics for liver transplant patients at University
Hospitals Birmingham (UHB) NHS Foundation Trust
The UHB NHS Foundation Trust Liver and Hepato-
Pancreato-Biliary (HPB) Unit is one of the largest in the
UK, performing over 250 liver transplants annually.
Once patients are considered clinically stable (usually
1 year post-transplant), they must attend the hospital
regularly for ongoing monitoring (follow-up appoint-
ments every 3 or 6 months). As one of only six specialist
adult liver transplant centres in the UK, the Liver and
HPB Unit covers an extensive catchment area, and many
transplant patients travel large distances to attend
follow-up appointments. In collaboration with patients
and clinicians, UHB has developed a video clinic tool
that is accessible via the Trust patient records portal
(myhealth@QEHB). The portal was developed by the
Technical Development and Informatics team at the
Trust, and is currently used by over 7000 patients across
40 clinical specialties. It allows patients to remotely ac-
cess some of their clinical information, including letters,
laboratory results, email correspondence with their
consultant and GP referrals, and patients can co-manage
their treatment plans with the relevant clinicians.
Patients can also view appointments, receive reminders,
upload/share files on the system and interact with other
patients to create their own peer-support networks.
Of the 3000 liver transplant patients considered stable
at any one time at UHB, approximately 1000 currently use
myhealth@QEHB and the Liver and HPB Unit is introdu-
cing video clinic appointments (termed myVideoClinic)
via the portal for these patients. Video clinics will allow
routine 3 or 6 monthly hospital appointments to be car-
ried out remotely via a secure video and/or voice link be-
tween the patient and their hospital consultant.
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MyVideoClinic will also allow patients to pre-specify three
questions/topics that they would like to discuss during
their video clinic, and an audio recording of the video
clinic will be made available in their patient record after
their appointment. Patients using the video clinic service
will need to have the relevant clinical testing for each ap-
pointment (blood tests, weight and blood pressure mea-
surements) carried out at a GP practice or dialysis centre
local to their home and the test results must be uploaded
to the portal prior to each myVideoClinic appointment.
Audit data collected from one of the UHB liver clinics
in early 2017 showed that, although satisfaction with out-
patient care in liver transplant patients is generally high
(as measured by the modified Visit-Specific Satisfaction
Instrument, VSQ-9) [26], satisfaction was significantly
lower in the specific VSQ-9 domains of ‘convenience of
location’, ‘getting through to the office by phone’ and
‘length of time waiting’ when these were compared to
other domains (n = 83; p < 0.0001). Perceived conveni-
ence, ease of contacting the hospital and waiting times are
therefore all aspects of patient satisfaction that could
potentially be improved by offering video clinics and
introducing flexibility in how patients receive their post-
transplant outpatient care. MyVideoClinic may also lower
patient and secondary care costs.
This protocol outlines a pragmatic, two-armed, parallel
group, statistician-blinded randomised evaluation de-
signed to assess the effectiveness of providing video
clinics as an alternative to standard face-to-face consul-
tations in delivering routine follow-up care for clinically
stable liver transplant patients.
Methods/Design
The protocol structure and content follows the SPIRIT
guidelines (see Additional file 1 for checklist) [27]. A com-
pleted SPIRIT figure shows the schedule of recruitment,
interventions and assessments (Fig. 1).
Aims
The primary aim is to assess whether the option of
myVideoClinic can increase patient satisfaction in the
VSQ-9 domains of ‘convenience of location’, ‘getting
through to the office by phone’ and ‘length of time wait-
ing’ compared to standard care (face-to-face consulta-
tions) for clinically stable liver transplant patients.
The secondary aims are to:
1. Assess the impact of myVideoClinic on patient
satisfaction in the other six VSQ-9 domains
2. Assess whether myVideoClinic can improve patient
health-related quality of life (HRQoL)
3. Evaluate the patient and secondary care costs associated
with myVideoClinic
4. Evaluate health service use and the number
(and length) of clinical contacts
5. Review the technical performance of the video clinic
6. Review the feasibility of clinical testing being
performed locally at the patient’s home
7. Review questionnaire completion rates
8. Evaluate the effect of the video clinic on travel time
9. Explore patients’ and carers’ opinions and experiences
of myVideoClinic
10. Explore health professionals’ opinions and experiences
of myVideoClinic
Participants
Patients will be recruited from four outpatient liver
clinics at the Queen Elizabeth Hospital Birmingham
(QEHB) (primary sclerosing cholangitis, primary biliary
cholangitis, alcoholic liver disease and autoimmune
hepatitis). Each year, approximately 267 patients at 1 to
5 years post-transplant attend routine hospital appoint-
ments at QEHB.
Participant inclusion criteria
1. Have had a liver transplant at least 1 year and no
more than 5 years prior to study baseline
2. Aged 18 or over
3. Considered clinically stable by their consultant
4. Have access to myhealth@QEHB (or agree to sign up)
5. Able to arrange for clinical testing (blood tests,
weight and blood pressure) to be undertaken locally
at a GP practice or dialysis centre and the results
uploaded onto myhealth@QEHB prior to the
myVideoClinic appointment
6. Have access to a computing device (e.g. desktop
computer or laptop) running an operating system
compatible with the video clinic software, as well as
a camera and internet connection to allow access to
myVideoClinic from home
7. Able to consent to participate in the study
Participant exclusion criteria
1. Unable to speak and/or read English
2. Unable to comply with study follow-up procedure
(completion of electronic questionnaires)
3. Involvement in another research study or clinical
trial involving ongoing questionnaire completion
Recruitment and consent
Prior to each clinic where recruitment is taking place, a
member of the clinical team will screen the day’s clinic
list to identify eligible patients on the basis of time since
transplant and age (inclusion criteria 1 and 2). Patients
who meet these criteria will have the study introduced
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to them at the end of their routine outpatient appoint-
ment and their further eligibility assessed against inclu-
sion criteria 3 to 7. The consultant will give eligible
patients a Participant Information Sheet and those inter-
ested in study participation will have the opportunity to
discuss the study with a member of the University of
Birmingham research team. The research team will take
written informed consent during the clinic from patients
who wish to participate and the latter will complete a
baseline questionnaire prior to randomisation. Patients
who require more time to consider participation will be
able to take the study information away and will be con-
tacted by telephone within 7 days by a member of the
research team. If a patient agrees to take part over the
telephone, a consent form and baseline questionnaire
will be posted to them along with a reply-paid envelope
for return of the completed documents to the University
of Birmingham. Once recruited, participants will stay in
the study for 12 months. This will equate to between
two and four follow-up appointments since the partici-
pants’ usual appointment schedule and frequency will
continue to be defined by clinical need regardless of
group allocation.
If a patient does not wish to participate in the study,
their reason for refusal will be recorded, along with rou-
tinely collected information (age, sex and clinic attended).
To further understand reasons for participants not taking
part, a selection of non-participating patients (n = 4) will
be invited to take part in a short semi-structured interview
(see qualitative study section).
Fig. 1 SPIRIT Schedule of enrolment, interventions, and assessments
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Randomisation and blinding
After giving consent and completing the baseline ques-
tionnaire, participating patients will be randomised in a
1:1 ratio to either the intervention (myVideoClinic) or
control (standard care) arm of the study using the Graph-
Pad online randomisation tool [28]. Participants will be
randomised by the member of the research team who has
taken participant consent. Patients randomised to the
myVideoClinic group will be registered on the myVideo-
Clinic system and given printed information on how to ac-
cess an online training tool that includes instructions on
how to use the video clinic. Patients from both study arms
will be registered on the myhealth@QEHB data collection
system. Due to the nature of the intervention, blinding of
study participants or clinical staff administering myVideo-
Clinic will not be possible. The statistician analysing the
primary outcome data will be blinded to each participant’s
study group for the intention-to-treat analysis.
Intervention group
Patients randomised to the myVideoClinic group will be
sent appointments for their video clinic through the post
and will receive standard text reminders about their ap-
pointment. Patients will be required to have their clinical
tests (blood test, weight and blood pressure) carried out
locally at their GP practice or at a nearby dialysis centre
and make the test results available through myhealth@-
QEHB before each video clinic appointment. At each ap-
pointment, patients will log in to myhealth@QEHB and
speak to their consultant via an embedded video link or
voice call (depending on their internet bandwidth).
Video clinics will use the secure system Vidyo as the
videoconferencing platform. In addition to having their
follow-up appointment via myVideoClinic, the system
will allow patients to submit up to three questions or
topics prior to their appointment that they would like to
discuss with their clinician, and patients will be able to
access an audio recording of the video clinic from their
patient record after each appointment.
If there are any technical issues with myVideoClinic
during a video appointment, the consultant will tele-
phone the patient to finish the appointment and sched-
ule a face-to-face appointment if necessary. All instances
where appointment rescheduling has occurred will be
recorded by the clinician. If patients in the intervention
group experience any technical problems with myVideo-
Clinic during the study, they are advised to contact the
myhealth@QEHB support team.
Control group
Patients randomised to the control group will receive
standard face-to-face care at the hospital and will not be
offered video clinics. They will receive standard written
notifications of the date and time of their appointment
and routine text reminders, and will also complete their
clinical tests in hospital on the day of their appointment,
the results of which will be reviewed by the clinician
after each patient’s appointment.
Crossover between study arms
Patients allocated to the intervention group will be made
aware that the intervention is the option of having a
video clinic as an alternative to face-to-face appoint-
ments and that they can ask to come to the hospital for
a standard face-to-face appointment if they wish. They
will still be able to have a video clinic for their next ap-
pointment as long as they complete their clinical tests
locally. Clinical staff will also be able to change patients
from using myVideoClinic to a standard face-to-face ap-
pointment if (1) the patient has requested this, (2) there
is a clinical need to see the patient face-to-face, or (3) if
a consultant has not seen the results of pre-appointment
clinical testing for a myVideoClinic patient for two suc-
cessive appointments. Staff will be asked to record any
reasons for changing patients from myVideoClinic to
standard care. The attendance to a face-to-face appoint-
ment by a patient assigned to the video clinic group will
not be treated as study withdrawal as we have allowed
for patients in the video clinic group to crossover be-
tween face-to-face appointments and video clinics for
clinical reasons and because pilot work has shown that
patients have a preference for flexibility. Crossover be-
tween study arms will be monitored, recorded and re-
ported in both interim and main study analyses and will
be discussed with the study’s independent monitoring
group if crossover exceeds 60%.
Outcome measures and data collection
Study outcomes and methods of data collection are sum-
marised in Table 1.
Primary outcome measure
The combined satisfaction score for three domains of
the modified VSQ-9 (convenience of location, getting
through to the office by phone and length of time wait-
ing) is the primary outcome for this study [26]. The
VSQ-9 has been validated and used in previous studies
conducted in different health settings [29], and an earlier
version of this questionnaire (SVQ13) was used in a ran-
domised controlled trial of virtual outreach in a UK con-
text [30]. The VSQ-9 asks participants to rate their
satisfaction with various aspects of their clinic appoint-
ment on a 5-point scale (poor, fair, good, very good, ex-
cellent). Scores are then transformed into a 0–100 linear
scale, where higher scores denote higher levels of satis-
faction. VSQ-9 data will be collected at baseline and
after every video clinic or face-to-face appointment via
patient questionnaires. A difference of 10 points between
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the intervention and control groups in the three selected
domains of the VSQ-9 at study end (12 months) will be
taken as clinically significant [30].
Secondary outcome measures
Secondary outcomes include satisfaction scores for the
other six domains of the VSQ-9 (collected at baseline
and after each appointment); routinely collected clinical
data from patient records; number and length of clinical
contacts; health service use; patient and secondary care
costs associated with video clinics and face-to-face ap-
pointments; patient travel requirements; whether pa-
tients in the intervention group have been able to have
clinical tests done locally before their appointment;
post-appointment questionnaire completion rates;
Table 1 Outcome measures, data collection instruments and format
Outcome measure Data collection instrument Format
Primary outcome
(Change in) satisfaction in the VSQ-9 domains
of ‘convenience of location’, ‘getting through
to the office by phone’ and ‘length of time waiting’
Modified Visit-Specific Satisfaction instrument
(VSQ-9) [26] within patient questionnaire
Baseline: paper
At the following timepoints, after each
appointment, in electronic or papera format:
3 months (if applicable)
6 months
9 months (if applicable)
12 months
Secondary outcomes
Patient-reported health-related quality of life EQ-5D-5 L [31] within patient questionnaire Baseline: paper
6 months: electronic or paper
12 months: electronic or paper
Patient satisfaction scores in the other six
VSQ-9 domains
VSQ-9 [26] within patient questionnaire Baseline: paper
At the following timepoints, after each
appointment, in electronic or papera format:
3 months (if applicable)
6 months
9 months (if applicable)
12 months
Routinely collected clinical outcomes Patient records Routinely collected metrics
Number and length of clinical contacts,
and instances of appointment
non-attendance
Length of appointment, phone calls,
myhealth@QEHB correspondence,
crossover between study arms
Routinely collected metrics
Clinician reporting
Case report forms
Health service use Patient questionnaire Baseline: paper
At the following timepoints, after each
appointment, in electronic or papera format:
6 months
12 months
Costs (NHS perspective and societal perspective) Patient questionnaire and routinely
collected data
Baseline: paper
At the following timepoints, after each
appointment, in electronic or papera format:
3 months (if applicable),
6 months
9 months (if applicable)
12 months
Routinely collected metrics
MyVideoClinic system performance Failed appointments, service outages,
telephone consultations
Routinely collected metrics
Clinical tests performed locally prior to video
clinic appointment
Blood tests, blood pressure and weight Case report form completed by clinician
Patient, carer and clinician experience Semi-structured interviews Semi-structured interviews
Questionnaire completion rates Number of questionnaires completed Baseline: paper
At the following timepoints, after each
appointment, in electronic or papera format:
3 months (if applicable)
6 months
9 months (if applicable)
12 months
aIf any patients experience technical issues providing data electronically, paper versions of the relevant questionnaires and reply-paid envelopes will be posted
directly to their home address for completion
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patient, carer and clinician experience; technical data on
myVideoClinic system performance; and HRQoL.
HRQoL data will be collected at baseline, 6 months and
study end using the EQ-5D-5 L [31], which assesses pa-
tient functioning and wellbeing with respect to mobility,
self-care, usual activities, pain/discomfort and anxiety or
depression. Levels of difficulty in each of these areas are
reported using a five-point ordinal scale, the combination
of which gives each patient a health profile. Although it is
recommended that quality of life for liver transplant pa-
tients should be measured using both a generic quality of
life questionnaire and a disease-specific instrument, a pre-
cise and reliable measure of quality of life for liver trans-
plant patients could not be identified [32, 33]. The
EQ-5D-5 L is straightforward to complete, can be admin-
istered in different ways, can be used as a utility measure
and has been used in previous studies with liver transplant
patients [33, 34].
Data collection time points
Figure 2 summarises the time points for data collection
for patients in the intervention and control groups.
Baseline
All patients who have consented to participate in the
study will complete baseline questionnaires before being
told the outcome of randomisation. Baseline question-
naires will record the following information:
 Sociodemographics (e.g. home postcode, sex, age,
ethnicity, employment status)
 Clinical information (e.g. diagnosis, comorbidities,
time since transplant)
 Current computer usage
 Patient satisfaction (modified VSQ-9)
 HRQoL (EQ-5D-5 L)
 Costs (e.g. healthcare use, travel and personal
expenses associated with appointment attendance)
Follow-up
Patients will complete patient satisfaction and summary
cost questionnaires after each myVideoClinic or standard
hospital appointment. For participants on a 3-monthly
follow-up schedule, data will be collected at baseline and
at 3, 6, 9 and 12 months. For participants on a 6-monthly
follow-up schedule, data will be collected at baseline and
at 6 and 12 months. For all participants, the 6- and
12-month questionnaires will collect full data on satisfac-
tion, costs (e.g. health service use, travel and personal ex-
penses), IT issues and HRQoL. Patients who also have
appointments at 3 and 9 months after baseline will
complete shorter questionnaires at these time points,
Fig. 2 Time points for data collection
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covering satisfaction and costs only. Questionnaires will
be sent to patients in both study arms electronically
through the myhealth@QEHB system no more than 7 days
after each appointment.
Qualitative study
In accordance with Medical Research Council guidelines
for evaluating complex interventions [35], an embedded
qualitative study will explore patient, carer/family mem-
ber and healthcare professionals’ experiences and per-
ceptions of myVideoClinic. Semi-structured interviews
will be undertaken with the following groups:
1. Patients randomised to the standard care group (n = 4)
2. Patients randomised to myVideoClinic
(intervention) group (n = 8)
3. Carers/family members of patients in the
intervention and control groups (n = 6)
4. Patients who did not wish to take part in the
randomised evaluation (n = 4)
5. Healthcare professionals involved in the care of the
intervention patient group (n = 14)
Patients
Patients randomised to the intervention group will be
stratified according to their degree of engagement with
the intervention (patients completing 50% or fewer of
their scheduled video clinic appointments vs. those com-
pleting more than 50%). Patients will be purposively sam-
pled to ensure diversity on key variables such as age and
sex. Selected patients will be invited to take part in a
semi-structured interview to explore their opinions or ex-
periences of using the myVideoClinic and any suggestions
on how it could be improved at the end of their involve-
ment in the study (n = 8). Purposively sampled patients in
the control group (n = 4) will also be interviewed about
their experiences of participating in the study.
Carers/family members
Carers/family members of patients being interviewed at
the end of the study (n = 6) will be invited to take part
in an interview to explore their experiences of caring
for/living with a patient in the video clinic study and any
impact of study participation on them.
Patients who do not wish to take part in the randomised
evaluation
A small number of eligible patients (n = 4) who decline
participation in the study will be interviewed to discuss
their reasons for not taking part. This will provide im-
portant information that may inform the subsequent
rollout of video clinics to other clinical specialties or
sites if the intervention is found to be effective.
Health professionals
A purposive sample of 14 health professionals (clinicians
who administer consultations, n = 8; staff who administer
clinical tests at the hospital, n = 2; primary care staff ad-
ministering clinical tests locally, n = 4) will be interviewed
at the end of the study. Interviews will explore staff experi-
ences of the myVideoClinic system, including any per-
ceived advantages (e.g. cost, time and quality of care) and
disadvantages (e.g. lack of physical examination). Interviews
will provide information on how best to engage and sup-
port health professionals in adopting video clinics within
routine care if the intervention is considered effective.
Sample size and study power
The sample size for the study has been determined by the
effect size needed to detect a clinically significant (10
point) difference between intervention and control groups
in the primary outcome measure (patient satisfaction as
measured on three domains of the VSQ-9). Assuming a
normal distribution of satisfaction scores, a sample size of
62 patients per group would be sufficient to detect a
10-point difference in VSQ-9 scores between groups at
80% power and an alpha of 0.05. Over a 12 month period,
an estimated 267 eligible patients will be available for re-
cruitment to the study from the four liver clinics of inter-
est. Annually, approximately 1% of liver transplant
patients at UHB undergo a re-transplant and 2% die.
Thus, around 21 patients per month will be eligible for re-
cruitment. Audit data collected from one liver clinic in
early 2017 suggest that approximately 60% of eligible pa-
tients will be willing to participate in the study (13 per
month). A previous randomised controlled study of video
clinics in diabetes care reported an attrition rate of 30%
[12]. Applying this attrition rate to our patient sample,
and allowing for participant withdrawals, missing data and
losses to follow-up, the required sample size for the study
is 90 per group (n = 180 total). Recruiting at a rate of 13
patients per month, we anticipate recruitment to take ap-
proximately 14 months in total (Fig. 3).
Statistical analysis
An interim analysis will be undertaken once 25% of the
target recruitment sample have completed two appoint-
ments. This interim analysis will focus on crossover
from the intervention to control groups due to patients
being unable to complete their clinical testing locally.
The findings from this interim analysis will be discussed
with the study’s independent monitoring group as high
rates of crossover have implications for the feasibility of
the intervention and will reduce study power to detect
significant differences between intervention and control
arms in the outcomes of interest. The main data analysis
will be undertaken on an intention-to-treat basis,
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although an unblinded per protocol analysis will also be
performed for the primary outcome measure to assess
whether similar results are obtained with regard to any sta-
tistically significant findings. It is acknowledged that youn-
ger patients may potentially find the intervention more
beneficial due to greater familiarity with technology, so age
will be controlled for and a sensitivity analysis will assess
whether age has an independent effect on outcomes.
The characteristics of study participants at baseline will
be summarised descriptively, with comparison of propor-
tions tests used to assess any differences between
intervention and control groups on the basis of sociode-
mographic and clinical characteristics. Analysis of the pri-
mary outcome measure (difference between groups in
scores in three domains of the VSQ-9) will use independ-
ent t tests if data are normally distributed. If data are not
normally distributed, the Mann–Whitney U test will be
used. For patients with missing end-of-study VSQ-9 data,
their most recently collected data will be used in the ana-
lysis. If participant numbers allow, subgroup analysis will
assess patient satisfaction scores adjusting for the level of
engagement that intervention patients had with myVideo-
Clinic (i.e. those with 6 months or less of video clinic
appointments vs. those with more than 6 months of video
clinic appointments).
Secondary outcome measures will be analysed descrip-
tively where the same data have been collected from pa-
tients in both study arms (e.g. health service use). Where
secondary outcome data are relevant to the intervention
group only (e.g. the incidence of technical issues during
myVideoClinic appointments), these will be tabulated and
basic statistical analyses performed (numbers, percentages,
means/medians etc.). Attrition/withdrawal rates and rates
of questionnaire completion will be analysed for both
study arms and overall. Analysis of HRQoL data will follow
the recommendations in the EQ-5D-5 L User Guide [34].
Health state valuations will be calculated for each profile
based on pre-calculated scoring coefficients. Changes in
HRQoL between baseline and study end will be assessed
for each patient and both descriptive and comparative ana-
lyses will be performed to compare HRQoL between par-
ticipants in the intervention and control groups.
Economic analysis
A within-trial cost consequences analysis (CCA) will be
undertaken. CCA allows consideration of a number of out-
come measures alongside costs, rather than a pre-defined
single outcome measure, as would be the case in a cost
utility analysis using quality-adjusted life years. Base-case
analysis will be conducted from the NHS perspective, with
additional analyses from the societal perspective. The NHS
perspective will include health service resource utilisation
in terms of provider costs, commissioner costs (prices)
and costs that are sometimes paid for by patients (e.g.
travel). Analysis will also include data on NHS resource
use for patient appointments (e.g. number of face-to-face
appointments, myVideoClinic calls, telephone calls,
emails) and costs of clinical tests. The societal perspective
will include non-NHS costs, such as patients’ out-of-
pocket expenses (e.g. travel costs, car parking, childcare
costs), and wider costs such as productivity loss due to ab-
sence from work. The CCA will include a sensitivity ana-
lysis to model the cost consequences of a number of
different scenarios, whereby patients take up different
numbers of appointments and different proportions of pa-
tients take up myVideoClinic. Including both the NHS
and societal perspectives will provide a full picture of how
video clinics affect the financial burden on both the NHS
and patients and may help to inform the development of
new payment currencies for patient management. This is
important in terms of the acceptability of myVideoClinic
to the provider and commissioners because any move
away from traditional face-to-face appointments risks a
loss of provider income, unless locally agreed funding ar-
rangements are implemented, which reflect the interven-
tion’s aims to promote more efficient use of resources.
Fig. 3 Recruitment rate
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Qualitative data
All interviews will be audio-recorded, transcribed verba-
tim and analysed using thematic analysis. The thematic
analysis will be undertaken in line with the methodology
outlined by Braun and Clarke [36]; 10% of the transcripts
will be independently coded by a second researcher and
compared, discussed and amended prior to defining the
themes. Qualitative data will be analysed as data is col-
lected to allow emerging themes to be explored in later
interviews.
Safety
The overall clinical responsibility and welfare of patients
involved in the study will remain with the consultant who
is providing their care and the clinical care the patient re-
ceives will not change. Any serious adverse events or ad-
verse events reported through myhealth@QEHB or during
interviews will be reported to the clinical lead immediately
by the informatics team or researcher. The clinical lead
will then notify the consultant responsible for the care of
the patient to ensure this is dealt with immediately.
Data monitoring
The research team and study steering group will be ac-
countable throughout the study to an independent mon-
itoring group, which will meet every 6 to 9 months. The
independent monitoring group members will participate
in discussions regarding study progress, review an un-
blinded report on interim study data (e.g. recruitment
rates and interim analysis results) and offer independent
advice to the study team.
Data management and participant confidentiality
All patient information will remain confidential through-
out the study as required by ethical and research govern-
ance approvals. At the initial eligibility screening stage,
an eligibility case report form will be completed by the
patient’s consultant, which records patient initials, age
and sex. Once a patient has given written consent to be
involved in the study, a randomisation case report form
will be completed by a member of the research team
and the participant assigned a unique, anonymised iden-
tifier. Members of the research team will have access to
patient-identifiable data during the study, but this will
only be after participants have given consent. All elec-
tronic files will be held at the University of Birmingham
on password-protected secure university servers to
which only members of the research team will have ac-
cess. Paper copies of research data or study documenta-
tion will be held securely in a locked archive in a locked
office in a swipe-card restricted area of the University of
Birmingham Institute of Applied Health Research.
Discussion
The myVideoClinic study is patient centred and has been
designed with input from patients, clinicians, researchers
and IT staff. It is anticipated that myVideoClinic will util-
ise technology to improve patient satisfaction with their
care. In addition, myVideoClinic could provide cost and
time savings for patients, removing the need to travel long
distances for outpatient appointments. Findings from this
research could be applicable to a wide range of settings
that could use video clinics. The embedded qualitative
study will allow the views of patients, carers/family mem-
bers and healthcare professionals on the video clinic to be
explored. These findings will allow a more in-depth un-
derstanding of how the video clinic was beneficial or how
it could be improved for future practice.
Study status
Study recruitment commenced on March 12, 2018, and
is anticipated to continue until May 2019.
Additional file
Additional file 1: SPIRIT 2013 33-item checklist. (DOC 121 kb)
Abbreviations
CCA: cost consequences analysis; GP: General Practitioner; HPB: hepato-
pancreato-biliary; HRQoL: health-related quality of life; QEHB: Queen Elizabeth
Hospital Birmingham; UHB: University Hospitals Birmingham; VSQ-9: Visit-
Specific Satisfaction Instrument
Acknowledgements
We would like to thank Bridget Gunson for providing information to inform
study design; the CLAHRCWM Theme 4 PPI group, CLAHRCWM Theme 4
Steering group, Aziz Sheikh and Paul Shekelle for providing feedback on
study design and documentation; Rui Duarte and Celia Taylor for input to
developing study questionnaires and economic analyses; Foyzul Rahman
(steering group member from December 2016 to June 2017) for providing
administrative support, and Katherine Arndtz, Gideon Hirschfield and Jayne
Parry for collaborating on questionnaire development for the pre-study audit
of outpatient care for liver patients. The myhealth@QEHB team at University
Hospitals Birmingham NHS Foundation Trust developed the video clinic
system, and we would like to thank Jim Williams (team lead), Foyzal Miah,
Katie Squire and Luke Sharkey for their input to developing appropriate
study metrics. Lastly, we would like to thank the independent monitoring
group (Professor Theo Arvanitis, Professor of e-Health Innovation and Head
of Research at the Institute of Digital Healthcare, University of Warwick;
Richard Aspinall, Consultant in Gastroenterology & Hepatology, Portsmouth
Hospitals NHS Trust, and Eleanor Walsh, Senior Research Associate, University
of Bristol), for supporting this study.
Study sponsor
The study is sponsored by the University of Birmingham. Contact details for
the sponsor are as follows:
Dr Sean Jennings, Research Governance and Ethics Manager, University of
Birmingham, Edgbaston, B15 2TT; Email:
researchgovernance@contacts.bham.ac.uk; Phone: 0121 415 8011.
Dissemination
Study findings will be presented at academic conferences and published in
peer-reviewed journals. Authorship eligibility for study outputs will be
determined by the International Committee of Medical Journal Editors
recommendations. Findings will also be disseminated to key stakeholders
locally and will inform how outpatient care is provided to liver transplant
patients at UHB. A CLAHRC BITE (Brokering Innovation Through Evidence) will
be produced. BITEs are designed to be accessible, bite-sized summaries
O’Connell Francischetto et al. Trials          (2018) 19:574 Page 10 of 12
of findings from published work undertaken by CLAHRCWM. The BITE
will be available on the CLAHRCWM website and will be sent via the
myhealth@QEHB system to those who took part in the study.
On behalf of the myVideoClinic randomised evaluation steering group
Gill Combes (University of Birmingham)
Sarah Damery (University of Birmingham)
Eric Deeson (Patient and Public Representative)
James Ferguson, Chair (University Hospitals Birmingham NHS Foundation Trust)
Janet Jones (University of Birmingham)
Foyzal Miah (University Hospitals Birmingham NHS Foundation Trust)
Pamela Nayyar (University of Birmingham)
Elaine O’Connell Francischetto (University of Birmingham)
Aziz Sheikh (University of Edinburgh)
Katie Squire (University Hospitals Birmingham NHS Foundation Trust)
Funding
This research is funded by the National Institute for Health Research (NIHR)
Collaboration for Leadership in Applied Health Research and Care West
Midlands (CLAHRCWM). The views expressed in this article are those of the
author(s) and not necessarily those of the NHS, the NIHR or the Department
of Health and Social Care. The funder has had no role in study design, nor
will they have a role in the collection, management, analysis and interpretation
of data, writing reports of study findings or the decision to submit reports for
publication.
Availability of data and materials
As this is a study protocol, the manuscript does not contain any data.
The datasets generated within this research study will not be publicly available
as study participants have not given consent for the wider sharing of their
participant-level data, even in anonymised form.
Authors’ contributions
EOF, SD, JF and GC conceived and designed the study. EOF produced the
initial draft of the protocol, with input from SD and GC. All authors critically
reviewed the manuscript and have read and approved the final version.
Ethics approval and consent to participate
Study protocol version 1.2 (25/09/2017) has been approved by the NHS
Health Research Authority and received a favourable ethical opinion from
the West Midlands Solihull Research Ethics Committee on October 24, 2017
(Ref: 17/WM/0338). Research governance approval was obtained from
University Hospitals Birmingham NHS Foundation Trust in February 2018
(Ref: RRK6080). The study is sponsored by the University of Birmingham.
Responsibility for the conduct of the research, analysis of the data and publication
of the findings will remain with the research team and steering group.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Institute of Applied Health Research, Murray Learning Centre, University of
Birmingham, Edgbaston, West Midlands B15 2TT, UK. 2University Hospitals
Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Mindelsohn
Way, Edgbaston, West Midlands B15 2GW, UK. 3NIHR Birmingham Biomedical
Research Centre, University Hospitals Birmingham NHS Foundation Trust and
University of Birmingham, Mindelsohn Way, Edgbaston, West Midlands B15
2GW, UK.
Received: 16 April 2018 Accepted: 29 September 2018
References
1. Department of Health. 2010 to 2015 Government Policy: Long Term Health
Conditions. https://www.gov.uk/government/publications/2010-to-2015-
government-policy-long-term-health-conditions/2010-to-2015-government-
policy-long-term-health-conditions. Accessed 20 Jan 2018.
2. Department of Health. The Government’s Mandate to NHS England for
2017–18. https://www.gov.uk/government/uploads/system/uploads/
attachment_data/file/692140/NHSE_Mandate__2017-18_revised.pdf.
Accessed 20 Jan 2018.
3. Honeyman M, Dunn P, McKenna H. A Digital NHS? An Introduction to the
Digital Agenda and Plans for Implementation. London: Kings Fund; 2016.
4. Wachter RM. Making IT Work: Harnessing the Power of Health Information
Technology to Improve Care in England. https://www.gov.uk/government/
uploads/system/uploads/attachment_data/file/550899/Watcher_Exec_
Summary_Accessible.pdf. Accessed 15 Mar 2018.
5. Flodgren G, Rachas A, Farmer AJ, Inzitari M, Shepperd S. Interactive
telemedicine: effects on professional practice and health care outcomes.
Cochrane Database Syst Rev. 2015;7(9):CD002098.
6. Kings Fund. Beverley Bryant: Enabling Patient-Centred Care through
Information and Technology. http://www.kingsfund.org.uk/audio-video/
beverley-bryant-enabling-patient-centred-care-through-information-and-
technology. Accessed 5 Sept 2017.
7. Kings Fund. Applications in Home and Health Care Settings. http://www.
kingsfund.org.uk/time-to-think-differently/trends/information-technologies/
applications-home-and-health-care-settings. Accessed 10 July 2017.
8. de Lusignan S, Mold F, Sheikh A, Majeed A, Wyatt JC, Quinn T, et al.
Patients’ online access to their electronic health records and linked online
services: a systematic interpretative review. BMJ Open. 2014;4:e006021.
9. Armfield NR, Gray LC, Smith AC. Clinical use of Skype: a review of the
evidence base. J Telemed Telecare. 2012;18(3):125–7.
10. Verhoeven F, van Gmert-Pijnen L, Dijkstra K, Nijland N, Seydel E, Steehouder
M. The contribution of teleconsultation and videoconferencing to diabetes
care: a systematic literature review. J Med Internet Res 2007;9(5):e37.
11. Viers BR, Lightner DJ, Rivera ME, Tollefson MK, Boorjian SA, Karnes RJ, et al.
Efficiency, satisfaction and costs for remote video visits following radical
prostatectomy: a randomized controlled trial. Eur Urol. 2015;68(4):729–35.
12. Basudev N, Crosby-Nwaobi R, Thomas S. A prospective randomized
controlled study of a virtual clinic integrating primary and specialist care for
patients with Type 2 diabetes mellitus. Diabet Med. 2015;33(6):768–76.
13. Wallace P, Haines A, Harrison R, Barber J, Thompson S, Jacklin P, et al. Joint
teleconsultations (virtual outreach) versus standard outpatient
appointments for patients referred by their general practitioner for a
specialist opinion: a randomised trial. Lancet. 2002;359(9322):1961–8.
14. Sharareh B, Schwartzkopf R. Effectiveness of telemedical applications in
postoperative follow-up after total joint arthroplasty. J Arthroplast. 2014;
29(5):918–22.
15. Sathiyakumar V, Apfeld JC, Obremskey WT, Thakore RV, Sethi MK. Prospective
randomized controlled trial using telemedicine for follow-ups in an orthopedic
trauma population: a pilot study. J Orthop Trauma. 2015;29(3):e139–45.
16. Wade VA, Karnon J, Elshaug AG, Hiller JE. A systematic review of economic
analyses of telehealth services using real time video communication. BMC
Health Serv Res. 2010;10:233.
17. Oakley AM, Kerr P, Duffill M, Rademaker M, Fleischi P, Bradford N, et al. Patient
cost-benefits of realtime teledermatology – a comparison of data from
Northern Ireland and New Zealand. J Telemed Telecare. 2000;6(2):91–101.
18. Wootton R, Bloomer SE, Corbett R, Eedy DJ, Hicks N, Lotery HE, et al.
Multicentre randomised control trial comparing real time teledermatology
with conventional outpatient dermatological care: societal cost-benefit
analysis. BMJ. 2000;320(7244):1252–6.
19. Jacklin PB, Roberts JA, Wallace P, Haines A, Harrison R, Barber JA, et al.
Virtual outreach: economic evaluation of joint teleconsultations for patients
referred by their general practitioner for a specialist opinion. BMJ. 2003;
327(7406):84.
20. Central Manchester University Hospitals NHS Foundation Trust. New Virtual
Clinics Introduced for Shoulder Surgery Patients at Trafford General. http://
www.cmft.nhs.uk/media-centre/latest-news/new-virtual-clinics-introduced-
for-shoulder-surgery-patients-at-trafford-general. Accessed 20 Jan 2017.
21. The Rotherham NHS Foundation Trust. Virtual Clinics. http://www.
therotherhamft.nhs.uk/virtual_clinics/. Accessed 20 Jan 2017.
22. U.S. Department of Veteran Affairs. VA Telehealth Services. http://www.
telehealth.va.gov/ccht/index.asp. Accessed 1 Feb 2017.
23. Centre for Reviews and Dissemination. Evidence Briefing on
Teleconsultation. https://www.york.ac.uk/media/crd/Teleconsultation.pdf.
Accessed 1 Feb 2017.
O’Connell Francischetto et al. Trials          (2018) 19:574 Page 11 of 12
24. Ekeland AG, Bowes A, Flottorp S. Effectiveness of telemedicine: a systematic
review of reviews. Int J Med Inform. 2010;79(11):736–71.
25. Mair F, Whitten P. Systematic review of studies of patient satisfaction with
telemedicine. BMJ. 2000;320(7248):1517–20.
26. RAND Health. Visit-Specific Satisfaction Instrument (VSQ-9). https://www.
rand.org/health/surveys_tools/vsq9.html. Accessed 13 Jun 2016.
27. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krle A-Jeric K, et
al. SPIRIT 2013 statement: defining standard protocol items for clinical trials.
Ann Intern Med. 2013;158:200–7.
28. GraphPad Software. Randomly Assign Subjects to Treatment Groups.
http://www.graphpad.com/quickcalcs/randomize1.cfm. Accessed 20 Jan 2016.
29. Rubin HR, Gandek B, Rogers WH, Kosinski M, McHorney CA, Ware JE Jr.
Patients’ ratings of outpatient visits in different practice settings. Results
from the Medical Outcomes Study. JAMA. 1993;270(7):835–40.
30. Wallace P, Barber J, Clayton W, Currell R, Fleming K, Garner P, et al. Virtual
outreach: a randomised controlled trial and economic evaluation of joint
teleconferenced medical consultations. Health Technol Assess. 2004;8(50):1–106.
31. EuroQol Group. EuroQol - a new facility for the measurement of health-
related quality of life. Health Policy. 1990;16(3):199–208.
32. Onghena L, Develtere W, Poppe C, Geerts A, Troisi R, Vanlander A, et al.
Quality of life after liver transplantation: State of the art. World J Hepatol.
2016;8(18):749–56.
33. Jay CL, Butt Z, Ladner DP, Skaro AI, Abecassis MM. A review of quality of life
instruments used in liver transplantation. J Hepatol. 2009;51(5):945–59.
34. EuroQol Group. EQ-5D User Guides. https://euroqol.org/wp-content/
uploads/2016/09/EQ-5D-5L_UserGuide_2015.pdf. Accessed 4 Apr 2016.
35. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process
evaluation of complex interventions: Medical Research Council guidance.
BMJ. 2015;350:h1258.
36. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol.
2006;3(2):77–101.
O’Connell Francischetto et al. Trials          (2018) 19:574 Page 12 of 12
